Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma
Source: OncLive, February 2024
Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.
Jeffrey S. Weber, MD, PhD, deputy director, codirector, Melanoma Research Program, New York University (NYU) Langone Perlmutter Cancer Center, Laura and Isaac Perlmutter Professor of Oncology, NYU Grossman School of Medicine, discusses the background for and rationale of the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881), which was conducted in patients with resected high-risk cutaneous melanoma.
At the 2023 ESMO Congress, Weber presented data from the clinical investigation of the addition of a personalized mRNA neoantigen vaccine to standard-of-care (SOC) pembrolizumab (Keytruda) in patients with resected stage IIIB, IIIC, IIID, and IV cutaneous melanoma. Findings from the investigation indicated that this treatment strategy enhanced survival outcomes compared with pembrolizumab alone in this patient population. These data supported the inference that monitoring circulating tumor DNA can offer valuable insights into the extent of benefit patients may derive from receiving an mRNA vaccine plus pembrolizumab.